Claire Mazumdar, who created Bicara and has served as chief executive for nearly seven years, is stepping down at the end of this year. Bicara Chief Operating Officer Ryan Cohlhepp will become CEO on Jan. 1, 2027, while Mazumdar will transition to strategic advisor and vice chair of the board of directors.
Mazumdar told BioSpace that she had long viewed Cohlhepp as the executive whose experience would be better suited for the company when it moved closer to commercial launch. That moment has arrived as Bicara advances ficerafusp alfa, a late-stage bifunctional EGFR/TGF-β antibody, as a first-line treatment for advanced head and neck cancer.
The transition
Mazumdar framed the move as an evolution of her role rather than an exit. She said her own background is more rooted in cancer biology and clinical development, while Cohlhepp brings commercial and operating experience that Bicara increasingly needs.
Cohlhepp has worked with Mazumdar for 10 years. Before Bicara, both were at Rheos Medicines, where he led research and development efforts. Earlier, he spent more than a decade in Takeda’s oncology division, including as vice president of marketing, operations and analytics.
That profile matters because Bicara is no longer just building an R&D story. The company is recruiting for a Phase 3 trial of ficerafusp alfa, with topline results expected in mid-2027. If the asset works, the next set of demands shifts from clinical execution to launch planning, organizational scaling and commercialization discipline. The signal in this handoff is that Bicara is aligning leadership with that transition before the registrational readout arrives, not after.
The road here
Mazumdar’s account of building Bicara also points to a familiar pressure point for emerging biotechs: fundraising can dominate the CEO role even for founders who come in with venture experience. Before founding Bicara, she had been a senior associate at Third Rock Ventures and expected fundraising to be more straightforward than it turned out to be.
Instead, she said she learned that many of her contacts were not yet decision-makers at their firms, and that early rejection was harder to absorb than she had anticipated. She also said that being a young female CEO meant having to build credibility before reputation could do much of the work, leaving the clinical data to speak for the company.
Bicara launched in March 2021 with $40 million in seed funding from parent company Biocon. It later skipped a series A and raised an oversubscribed $108 million series B. During Mazumdar’s previous maternity leave, Cohlhepp served as acting CEO around the time Bicara closed a $165 million Series C in December 2023, giving the company a practical test of the succession plan now becoming permanent.
Company building beyond the asset
Mazumdar tied part of Bicara’s identity to culture as well as capital and clinical progress. She said one of the best signals she received from employees was that they did not have the “Sunday scaries,” reflecting her emphasis on a hybrid work model and more sustainable hours.
She also described Bicara as a place where several women executives with three children or more have been able to continue rising in their careers, crediting both the company’s flexibility and support from male colleagues in maintaining that environment. Her comments suggest the founder sees organizational durability as one of her main achievements, alongside advancing the pipeline.
For investors and peers, the more material takeaway is that Bicara is trying to de-risk a common biotech bottleneck. Many founder-led companies wait too long to match leadership structure to the demands of a possible launch. By making the change ahead of a mid-2027 Phase 3 topline result, Bicara is signaling that the company views commercialization readiness as a strategic workstream in its own right, rather than a task to address only if the data are positive.
